Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

Nature Communications

Volumn 5, Issue , 2014, Pages

  Long, Georgina V ^a,b,c   Fung, Carina ^d,e   Menzies, Alexander M ^a,b,f   Pupo, Gulietta M ^e   Carlino, Matteo S ^a,e,f   Hyman, Jessica ^a,g   Shahheydari, Hamideh ^d,e   Tembe, Varsha ^e   Thompson, John F ^a,b,g   Saw, Robyn P ^a,b,g   Howle, Julie ^a,b,f   Hayward, Nicholas K ^h   Johansson, Peter ^h   Scolyer, Richard A ^a,b,g   Kefford, Richard F ^a,b,d,e   Rizos, Helen ^d,e  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Mater Hospital   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

^f WESTMEAD HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NRAS PROTEIN; RAS PROTEIN; TRAMETINIB; UNCLASSIFIED DRUG; AKT3 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; IMIDAZOLE DERIVATIVE; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NRAS PROTEIN, HUMAN; OXIME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; RAC1 PROTEIN; RAC1 PROTEIN, HUMAN;

INHIBITION; MUTATION; PIGMENT; TUMOR;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME REACTIVATION; EXOME; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; MALE; METASTATIC MELANOMA; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; DRUG RESISTANCE; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; SECONDARY; SKIN NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; GTP PHOSPHOHYDROLASES; HUMANS; IMIDAZOLES; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANOMA; MEMBRANE PROTEINS; OXIMES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDONES; PYRIMIDINONES; RAC1 GTP-BINDING PROTEIN; SKIN NEOPLASMS;

EID: 84923341318     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6694     Document Type: Article

References (60)

1. Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl. J. Med. 367, 1694-1703 (2012).
2. Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. New Engl. J. Med. doi:10.1056/NEJM.a1406037 (2014).
3. Robert, C. et al. COMBI-v: A randomised, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) to vemurafenib (V) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Ann. Oncol. 25, 1-41 (2014).
4. Larkin, J. et al. Combined Vemurafenib and Cobimetinib in BRAF-mutated melanoma. New Engl. J. Med. doi:10.1056/NEJM.a1408868 (2014).
5. Kefford, R. et al. Preliminary results from a phase Ib/II, open-label, doseescalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. ASCO Meet. 31, 9029 (2013).
6. Menzies, A. M. et al. Inter-And intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS ONE 9, e85004 (2014).
7. Rizos, H. et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin. Cancer Res. 20, 1965-1977 (2014).
8. Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80-93 (2014).
9. Van Allen, E. M. et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 4, 94-109 (2014).
10. Shi, H. et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat. Commun. 3, 724 (2012).
11. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
12. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387-390 (2011).
13. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085-3096 (2011).
14. Carlino, M. S. et al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Mol. Oncol. 15, 544-554 (2014).
15. Gowrishankar, K. et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J. Invest. Dermatol. 132, 1850-1859 (2012).
16. Wagle, N. et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 4, 61-68 (2014).
17. Villanueva, J. et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep. 4, 1090-1099 (2013).
18. Pratilas, C. A. et al. V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl Acad. Sci. USA 106, 4519-4524 (2009).
19. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
20. Johannessen, C. M. et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 504, 138-142 (2013).
21. Whittaker, S. R. et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 3, 350-362 (2013).
22. Mar, V. J. et al. BRAF/NRAS wild-Type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin. Cancer Res. 19, 4589-4598 (2013).
23. Davies, M. A. et al. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99, 1265-1268 (2008).
24. Nelen, M. R. et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6, 1383-1387 (1997).
25. Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014 (2012).
26. Watson, I. R. et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 74, 4845-4852 (2014).
27. Kawazu, M. et al. Transforming mutations of RAC guanosine triphosphatases in human cancers. Proc. Natl Acad. Sci. USA 110, 3029-3034 (2013).
28. Koh, J., Enders, G. H., Dynlacht, B. D. & Harlow, E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375, 506-510 (1995).
29. Ranade, K. et al. Mutations associated with familial melanoma impair p16INK4 function. Nat. Genet. 10, 114-116 (1995).
30. Martin, D. W., Munoz, R. M., Subler, M. A. & Deb, S. p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268, 13062-13067 (1993).
31. Yan, H. et al. IDH1 and IDH2 mutations in gliomas. New Engl. J. Med. 360, 765-773 (2009).
32. Dang, L. et al. Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
33. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
34. Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742-750 (2013).
35. Lassen, A. et al. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol. Cancer 13, 83 (2014).
36. Gilmartin, A. G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989-1000 (2011).
37. Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321 (2012).
38. Ussar, S. & Voss, T. MEK1 and MEK2, different regulators of the G1/S transition. J. Biol. Chem. 279, 43861-43869 (2004).
39. Khokhlatchev, A. et al. Reconstitution of mitogen-Activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases. J. Biol. Chem. 272, 11057-11062 (1997).
40. Sun, C. et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508, 118-122 (2014).
41. Eblen, S. T. et al. Mitogen-Activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion. Mol. Cell. Biol. 24, 2308-2317 (2004).
42. Catalanotti, F. et al. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat. Struct. Mol. Biol. 16, 294-303 (2009).
43. Nathanson, K. L. et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin. Cancer Res. 19, 4868-4878 (2013).
44. Paraiso, K. H. et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760 (2011).
45. Xing, F. et al. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31, 446-457 (2012).
46. Rubinstein, J. C. et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J. Transl. Med. 8, 67 (2010).
47. Menzies, A. M. et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249 (2012).
48. Falchook, G. S. et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901 (2012).
49. Ascierto, P. A. et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. 31, 3205-3211 (2013).
50. Long, G. V. et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAFmutant melanoma metastatic to the brain (BREAK-MB): a multicentre, openlabel, phase 2 trial. Lancet Oncol. 13, 1087-1095 (2012).
51. McArthur, G. A. et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 15, 323-332 (2014).
52. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
53. Mann, G. J. et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 133, 509-517 (2013).
54. Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010).
55. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
56. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
57. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
58. Carlino, M. S. et al. Anti-proliferative effects of continued mitogen activated protein kinase pathway inhibition following acquired resistance to BRAF and/ or MEK inhibition in melanoma. Mol. Cancer Ther. 12, 1332-1342 (2013).
59. Dull, T. et al. A third generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
60. Haferkamp, S. et al. Oncogene-induced senescence does not require the p16(INK4a) or p14ARF melanoma tumor suppressors. J. Invest. Dermatol. 129, 1983-1991 (2009).